Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29163981 | 1.00 | CTSK (0.38) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL17040320 | 0.86 | CTSK (0.43) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL28937411 | 0.85 | ATM (0.40) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL28937402 | 0.85 | ATM (0.40) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL16410288 | 0.84 | LMNA (0.42) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL18854512 | 0.84 | HTT (0.42) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL17041238 | 0.84 | CTSK (0.40) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL19234270 | 0.84 | LMNA (0.42) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL31693047 | 0.83 | CCR1 (0.47) | CTSKCTSSMAPTATMKMT2A | |
| SCHEMBL29164034 | 0.81 | CCR1 (0.39) | CTSKCTSSMAPTATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-25 | — | — | US | disclosed |
| EP-4322962-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500507-A | Phosphorus derivatives as novel SOS1 inhibitors | 拜耳公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022219035-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | SOST, PPM1D, SOS1 | CTSK 3708/4885CTSS 3487/4885MAPT 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.